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Background: WHO grade II gliomas are often approached by radiation therapy (RT). However, little is known about tumor re-
sponse and its potential impact on long-term survival. 
Patients and Methods: Patients subjected to RT were selected from the own database of WHO grade II gliomas diagnosed be-
tween 1991 and 2000. The volumetric tumor response after RT was assessed based on magnetic resonance imaging and graded 
according to standard criteria as complete, partial (PR, ≥ 50%), or minor (MR, 25% to < 50%). 
Results: There were 24 astrocytomas and three oligoastrocytomas. 21 patients (78%) were dead at follow-up (mean survival 74 
months). None of the patients had chemotherapy. Objective response occurred in 14 patients (52%, five PR and nine MR) but was 
not associated with overall survival. The vast majority of the tumors had no loss of heterozygosity (LOH) 1p and/or 19q (86%).
Conclusion: Approximately 50% of patients with astrocytic WHO grade II gliomas respond to RT despite the absence of LOH for 
1p/19q. The potential predictive factors for response and the impact of response on overall survival remain unclear. 
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Objektives Tumoransprechen nach Radiotherapie und Langzeitüberleben von Patienten mit astrozytären WHO-
Grad-II-Gliomen mit bekanntem LOH-1p/19q-Status  
Hintergrund: WHO-Grad-II-Gliome werden oft einer Radiotherapie (RT) zugeführt. Über das objektive Tumoransprechen und 
seine potentielle Auswirkung auf das Langzeitüberleben ist allerdings wenig bekannt. 
Patienten und Methodik: Aus der eigenen Datenbank von WHO-Grad-II-Gliomen wurden die einer RT unterzogenen Patienten 
eingeschlossen. Das volumetrische Ansprechen nach RT wurde anhand von Magnetresonanztomogrammen gemessen und nach den 
Standardkriterien eingestuft: komplett, partiell (PR, ≥ 50%) oder gering (MR, 25% bis < 50%). 
Ergebnisse: Es fanden sich 24 Astrozytome und drei Oligoastrozytome. Kein Patient erhielt eine Chemotherapie. Bei der Nachun-
tersuchung waren 21 Patienten (78%) gestorben (mittlere Überlebenszeit: 74 Monate). Ein objektives Ansprechen wurde bei 14 
Patienten verzeichnet (52%, fünf PR und neun MR), was jedoch nicht mit der Gesamtüberlebenszeit korrelierte. Die Mehrheit der 
Tumoren wies keinen Verlust an Heterozygotie (LOH) 1p/19q auf (86%). 
Schlussfolgerung: Ungefähr 50% der Patienten mit astrozytären WHO-Grad-II-Gliomen sprechen trotz fehlenden LOH 1p/19q auf 
eine RT an. Potentielle prädiktive Faktoren für das Tumoransprechen und dessen Einfluss auf die Gesamtüberlebenszeit bleiben 
unklar. 
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Introduction 
Radiation therapy (RT) is frequently used to treat adult 
patients with supratentorial WHO grade II gliomas [3, 6, 7, 
10–12, 16, 20]. However, the impact of RT on overall survival 
is unclear and the data on the frequency, extent and predic-
tive factors of objective tumor response after RT are almost 
inexistent for this group of patients [4, 25]. RT may be admin-
istered early after diagnosis (early radiation therapy [eRT]) 
or when the tumor progresses (delayed radiation therapy 
[dRT]). It was demonstrated that eRT improves progression-
free survival, but not overall survival, as compared with dRT 
[9, 21, 24, 25]. 
Prognostic factors for progression-free and overall surviv-
al in WHO grade II glioma patients include young age, good 
neurologic and overall performance status, small preopera-
tive tumor volume, lack of enhancement on imaging, oligo-
dendroglial histology, and possibly gross total resection [19]. 
Loss of heterozygosity (LOH) 1p/19q, which is typically but 
not exclusively associated with an oligodendroglial morphol-
ogy [1, 18, 22, 26], is clearly emerging as a strong prognostica-
tor of longer overall survival in this group of patients [14, 23, 
24, 26]. Also, LOH 1p/19q is a strong predictor of response to 
chemotherapy [1, 2, 8, 23] and some data suggest that it may be 
a predictor of response to RT [1]. 
In the present study, we analyzed tumor response after 
RT and long-term survival in a consecutive series of patients 
with WHO grade II gliomas diagnosed between 1991 and 
2000. In these patients we also assessed whether the tumors 
had LOH 1p36/19q13 or not. 
Patients and Methods 
This was an observational, retrospective, single-center study 
where data on patients with WHO grade II treated at our insti-
tution between 1991 and 2000 were collected prospectively. 
Clinical and Volumetric Data 
From our database of WHO grade II glioma patients [14, 15] 
we selected those subjected to RT. The survival data were 
updated in March 2005 for all patients. None of the patients 
had received chemotherapy by that time [14]. Digitalized pre-
RT and post-RT magnetic resonance images (MRIs) were 
interactively analyzed using a dedicated software (NIH Im-
age for Macintosh by Wayne Rasband, modified for use with 
Windows, © 2000 Scion Corporation), as described [15]. Tu-
mor volumes were measured based on the entire region of 
hyperintensity (compared to normal brain) in T2-weighted 
and FLAIR MRIs. Tumor response was assessed between 3 
and 12 months after RT and defined as minor (MR, reduction 
by ≥ 25% to < 50% of the initial tumor volume), partial (PR, 
≥ 50%), and complete (CR, no residual tumor) [13]. Progres-
sive disease (PD) was defined as an increase in tumor volume 
by ≥ 25%. Patients with CR, PR and MR were defined as re-
sponders, patients with stable disease (SD) or PD as nonre-
sponders. 
Radiation Therapy 
Our center recommends eRT for “high-risk” and dRT for 
“low-risk” patients [24]. High age (> 45 years), large residual 
tumor (> 5 cm cross sectional diameter or > 60 cm3), bihemi-
spheric involvement, midline shift, preoperative neurologic 
deficits, and a gemistocytic component were considered risk 
factors for early progression. In presence of two or more risk 
factors eRT was typically recommended. Delayed RT was 
performed at tumor progression, if the recurrent tumor was 
not considered operable. After CT based three dimensional 
planning, conformal RT was performed with a linear accelera-
tor (6-MV or 15-MV photons) using multiple fields. 54–60 Gy 
were administered in daily fractions of 1.8–2 Gy to the tumor 
region and approximately 2 cm of the adjacent brain but a 
maximum dose of 52 Gy on the optic nerves. 
LOH for Chromosomes 1p36 and 19q13 
Tumor DNA was extracted from formalin-fixed, paraf-
fin-embedded tissue. Reference (normal) DNA was iso-
lated either from the patient’s peripheral blood leukocytes 
or from tumor-free areas of paraffin-embedded specimens 
after careful microscopic analysis and subsequent dissec-
tion. Microsatellite markers for the chromosomal regions 
1p36.21–1p36.33 (D1S468, D1S1612, D1S228, D1S214), and 
19q13.31–19q13.41 (D19S219, D19S412, D19 HRC) were am-
plified by polymerase chain reaction, and analyzed for LOH, 
as described [14]. 
Statistical Analysis 
Patient  and therapy-related factors were tested for a possible 
correlation with response after RT. Fisher’s exact test based 
on cross-tables was performed to test the influence of age 
(≤ and > 40 years), gender, presence of any oligodendroglial 
component, presence of a gemistocytic component, 1p36 and 
19q13 status, and tumor volume (≤ and > 70 cm3). The impact 
of objective tumor response and of the timing of RT (eRT 
vs. dRT) on overall survival was analyzed using the unpaired 
t-test and Kaplan-Meier methods. The level of statistical 
significance was set at p < 0.05 for a two-tailed hypothesis. 
The software WinSTAT® for Excel 2003 was used for this 
analysis. 
Results 
Cohort’s Characteristics, Timing of Radiotherapy, 
and Overall Survival 
Out of the 79 patients diagnosed with WHO grade II glioma 
between 1991 and 2000 at the University Hospital of Bern, 
Switzerland, 47 received RT. Preoperative, postoperative and 
follow-up MRI exams for assessment of tumor response and 
progression were available for 27 patients, who were the focus 
of the present study. 
There were ten female and 17 male patients with a me-
dian age of 38 years (mean 42.5 ± 2.3 SEM [standard error of 
mean], range 26–67 years) at the time of diagnosis. The histo-
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logical diagnosis was oligoastrocytoma in three patients and 
astrocytoma in 24 patients. There was no oligodendroglioma. 
Early RT was performed in twelve patients after a mean of 
4.5 months following diagnosis (range 0–12 months); four pa-
tients had three risk factors (see Patients and Methods), seven 
patients had two risk factors (mainly large residual tumors and 
age), and one patient requested RT (patient’s choice). De-
layed RT was administered in 15 patients after a mean of 38 
months following diagnosis (range 18–72 months): 14 patients 
had tumor progression (with a new contrast enhancement in 
seven of them), one patient requested the treatment (patient’s 
choice). 
21 patients (78%) were dead at follow-up. The mean 
overall survival after diagnosis was 74 months (SEM 7.3, 
range 7–160 months). The mean follow-up of the six survivors 
was 113 months (range 62–160 months). None of the factors 
tested was found to be significantly associated with overall 
survival. However, male gender, dRT, and tumor volumes 
≤ 70 cm3 were positively associated with overall survival after 
diagnosis (Table 1). There was also a trend for longer over-
all survival in the patients without any evidence of malignant 
transformation on MRI (p = 0.13 for overall survival from the 
time of diagnosis; p = 0.1 for overall survival from the time 
of RT). 
Tumor Response, Predictive Factors, and Survival 
Overall, 14 patients (five after eRT and nine after dRT) showed 
an objective tumor response (52%): a PR in five (18.5%) and 
an MR in nine patients (33%). 13 patients had either SD (ten 
patients) or PD (three patients). The mean tumor volume was 
103 cm3 (SEM 16.6, range 16.6–332 cm3) before and 76.7 cm3 
(SEM 16.7, range 13–392 cm3) after RT. The mean interval 
to maximum tumor reduction was 6 months after RT (SEM 
0.7). Tumor regrowth was observed after a mean of 26 months 
(SEM 3.7). The graph plotting the changes of tumor volume 
over time after RT is shown in Figure 1. 
The LOH analysis for 1p or 19q was conclusive in 22 out 
of 27 patients (81.5%). Overall, only three patients (13.6%) 
had loss of either 1p (one patient), 19q (one patient), or both 
(one patient). Tumor response was observed in ten (52.6%) 
out of 19 patients without LOH 1p and/or 19q. Of the three 
patients with LOH of 1p and/or 19q, one had an MR and two 
an SD. The number of patients with LOH 1p36 and/or 19q13 
(three patients) was insufficient to test an impact on response 
Table 1. Statistical analysis for potential predictors of response to radiotherapy (RT) and overall survival. Fisher’s exact test based on two-by-two 
tables revealed no significant association of the analyzed factors with volumetric tumor response after RT. dRT: delayed radiotherapy; eRT: early 
radiotherapy; GC: gemistocytic component; LOH: loss of heterozygosity; NS: not significant; ODG: oligodendroglial component; SEM: standard 
error of mean. 
Tabelle 1. Statistische Analyse der möglichen prädiktiven Faktoren für das Ansprechen auf Radiotherapie (RT) und die Gesamtüberlebenszeit. Der 
Fisher’s Exact Test, basierend auf 2 × 2-Tabellen, ergab keine signifikante Assoziation der analysierten Faktoren mit der volumetrischen Tumorant-
wort auf RT. dRT: verzögerte/sekundäre Radiotherapie; eRT: frühe Radiotherapie; GC: gemistozytäre Komponente; LOH: Verlust der Heterozygotie; 
NS: nicht signifikant; ODG: oligodendrogliale Komponente; SEM: Standardfehler des Mittelwertes. 
Factor analyzed  Response    Overall survival
 Responders    Nonresponders   p-value    Mean survival after   p-value (t-test)
 (n = 14) (n = 13) (Fisher's exact test) diagnosis months)
Age ≤ 40 years   9   7 
0.7 (NS)
 72.4   (± 6.9 SEM) 
0.74 (NS)Age > 40 years    5   6  77.7   (± 16.7 SEM)
Male   8   9 
0.7 (NS)
 84.3   (± 9.5 SEM) 
0.0559 (NS)Female   6   4  55.6   (± 9.3 SEM) 
ODG   0   3 
0.69 (NS)
 a
No ODG 14 10  
GC   5   6 0.7 (NS) 70.1   (± SEM 7.5) 0.69 (NS)NO GC   9   7  76.1   (± SEM 11.4) 
Tumor volume ≤ 70 cm3   6   9 
0.25 (NS)
 82.5   (± SEM 10.2) 
0.18 (NS)Tumor volume > 70 cm3    8   4  62.7   (± SEM 9.9) 
eRT   5   7 
0.45 (NS)
 60.58 (± SEM 10.1) 
0.11 (NS)dRT   9   6  84.13 (± SEM 9.8) 
LOH 1p36   1   1 1 (NS) 
a
No LOH 1p36 11    8   
LOH 19q13   1   1 
1 (NS)
 a
No LOH 19q13 10    7   
Survival after XRT ≤ 60 months   9   9 
1 (NS)
 9 
1 (NS)Survival > 60 months    5   4  4 
Responders    79.86 (± SEM 11.1) 
0.39 (NS)Nonresponders    67      (± SEM 9.42) 
a low data available for t-test analysis 
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or survival (p = 1, Fisher’s exact test). No other factors were 
associated with tumor response (Table 1). 
The mean overall survival after diagnosis was longer for 
responders than for nonresponders (80 months ± 11 SEM vs. 
67 months ± 9.4 SEM). However, the difference did not reach 
statistical significance (t-test, Mann-Whitney test). This find-
ing was confirmed by the Kaplan-Meier analysis (Figure 2; 
p = 0.33). Also, the overall survival after RT (mean 51 months 
± 6.3 SEM, range 7–117 months) was no different in respond-
ers and nonresponders (Figure 2; p = 0.9). Comparing the 
seven patients with MRI evidence of malignant transforma-
tion with those without this evidence did not reveal signifi-
cant differences in terms of tumor response after RT (t-test, 
p = 0.8–0.9). 
Discussion 
To our knowledge, this is the first study analyzing objective 
tumor response in a cohort of adult patients with WHO grade 
II gliomas subjected to RT. A reduction in tumor volume after 
RT was observed in approximately 90% of the patients. The 
reduction in tumor volume met the criteria of an objective tu-
mor response in 14 out of 27 patients (52%). Tumor response 
reached its maximum approximately 6 months after RT, a 
finding that matches well what has been reported for pediatric 
low-grade gliomas [4].
A potential problem with our approach of measuring 
the tumor volume based on MRI [15] is that hyperintensity 
changes on T2-weighted and FLAIR images, especially in the 
long-term follow-up, can be side effects of radiation [5]. Even 
if postirradiation changes might interfere in the evaluation of 
tumor progression after RT in the long term, they should not 
influence the assessment of tumor response, which is charac-
terized by a reduction of the T2-hyperintense, neoplastic re-
gions relatively early after treatment. 
None of the factors tested as potential predictors of tu-
mor response were statistically significant. Bauman et al. sug-
gested a positive association between LOH 1p and survival 
after RT in oligodendroglioma patients [1]. LOH 1p/19q was 
a rare event in our series, as expected since the vast majority 
of the tumors were astrocytomas [17, 18]. The low incidence 
of LOH 1p/19q prevented us from assessing its potential, 
positive predictive value for response to RT. However, we 
could show, that an objective tumor response after RT oc-
curs in approximately half of the patients despite the absence 
of LOH 1p/19q. This finding may become important for pa-
tients’ management in the future. The ongoing, cooperative, 
EORTC trial 22033, in which patients with WHO grade II su-
pratentorial gliomas are stratified according to the 1p status 
and randomized to receive either RT or temozolomide has 
the potential for elucidating the predictive role of LOH 1p 
for RT in the future. 
The lack of a significant survival advantage for respond-
ers over nonresponders is somewhat surprising in the present 
series. The relatively small number of patients is a possible 
explanation (type 1 error). However, the length of follow-
up, with > 75% of the patients having died within that fol-
low-up, and the absence of a trend for a longer overall sur-
vival after RT in the responders suggest the validity of this 
finding. In fact, the major determinant of overall survival in 
patients with WHO grade II gliomas is the occurrence of ma-
Figures 1a and 1b. Changes in tumor volume after RT are shown for the 
14 responders (a) and the 13 nonresponders (b; see Patients and Meth-
ods). Please note that 10 out of 13 nonresponders had stable disease 
according to the definition but nevertheless showed a reduction in 
tumor volume after RT. 
Abbildungen 1a und 1b. Veränderungen des Tumorvolumens nach RT 
für 14 Responder (a) und 13 Nonresponder (b; see „Patients and Meth-
ods“). Man beachte, dass zwar 10 der 13 Nonresponder gemäß Defi-
nition einen unveränderten Volumenverlauf hatten; dennoch zeigte 
sich bei diesen Patienten eine Tumorvolumenreduktion nach der RT. 
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lignant transformation, as suggested by the large coopera-
tive study showing that RT can prolong the progression free 
survival but not the overall survival of WHO grade II glioma 
patients [25]. Even in a small series like ours, we found a 
clear trend for a shorter overall survival in patients with a 
“high-risk” profile for malignant transformation, that is in 
patients selected for eRT (n = 12) [25] and in patients with a 
new contrast enhancement before dRT (n = 7). Altogether, 
these data suggest that RT does not influence the cascade of 
events eventually leading to the malignant transformation of 
a WHO grade II glioma, which eventually determines overall 
survival. 
Conclusion 
We demonstrated that approximately half of the patients with 
a WHO grade II glioma show an objective response after RT, 
even in the absence of LOH 1p/19q. The impact of response to 
RT on overall survival and the factors predicting response to 
RT remain unclear. 
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